Retinal dysfunction in Alzheimer's disease mouse models

阿尔茨海默病小鼠模型的视网膜功能障碍

基本信息

项目摘要

Project Summary Alzheimer’s disease (AD) is the most common dementia resulting in progressive impairment in memory and thinking and affecting millions of older adults worldwide, with no cure. The eye, as part of the central nervous system, exhibits a range of defects in AD, such as retinal thinning, ganglion cell loss, microvascular deficit and Müller cell dysfunction. The eye provides a transparent window for studying neural and vascular defects, thus can aid in biomarker development in AD. This grant supplement will capitalize on this unique position of the eye in studying pathological aspects of AD with the potential to develop biomarkers for assessment of AD. It builds on the solid foundation of the current R01EY027779, including ocular phenotyping and functional assessment of Kif4.1 channels in Müller cells, but extends the work from diabetic retinopathy into AD. Late-onset AD (LOAD) is the most common form of AD, and genetics plays a critical role in AD pathogenesis, with apolipoprotein e4 (APOE4) as a leading factor. Model Organism Development & Evaluation of Late-Onset Alzheimer’s disease (MODEL-AD) is a consortium that is developing the next generation of mouse models relevant to LOAD and characterizing various phenotypes in these models. We will leverage this unique MODEL- AD resource to study the ocular phenotype in APOE4KI mice (LOAD-risk) in comparison to APOE3KI (LOAD- neutral). Our pragmatic study design will first characterize these mice in a series of visual function assays, explore their retinal transcriptome for markers of neurodegeneration and compare with that of brain tissue, and study Kir4.1 channels in Müller cells, where APOE4 is mainly concentrated. In a second set of studies, we will challenge these mice to high-fat diet treatment to study retinal function in the hyperglycemic milieu and test whether the presence of APOE4 genotype precipitates a diabetic retinopathy (DR) phenotype, the most common complication of diabetes. The above study design is based on our preliminary data which demonstrate a vascular deficit in the brain and increased blood glucose in response to a high-fat diet in APOE4 animal models. To ensure the success of the project, we have gathered a team of experts in both eye and AD research. The research in this supplement will advance the AD research field in a variety of ways: (i) study of retinal vasculature may aid in the early diagnosis of AD; (ii) transcriptomics will identify novel targets altered in AD retinas, which will help in understanding the disease pathogenesis and future drug development; (iii) brain Kir4.1 channels are downregulated in AD; however, how APOE4 affects their function is not known. Our studies will point towards studying mechanisms in this direction; (iv) DR is a blinding eye condition, and AD patients demonstrate a correlation with DR. Our studies will shed light on the link between these two pathologies; (v) our studies will contribute to MODEL-AD’s goal of characterizing the phenotype of AD models and establish a paradigm for ocular assessments of future models.
项目摘要 阿尔茨海默病(AD)是最常见的痴呆症,会导致记忆和 思考并影响全球数百万老年人,但没有治愈方法。眼睛,作为中枢神经的一部分 在AD中表现出一系列的缺陷,如视网膜变薄,神经节细胞丢失,微血管缺陷和 米勒细胞功能障碍。眼睛为研究神经和血管缺陷提供了一个透明的窗口,因此 可以帮助AD的生物标记物的发展。这项补助将利用眼睛的这一独特位置。 在研究AD的病理方面,有可能开发用于评估AD的生物标记物。它构建了 关于目前R01EY027779的坚实基础,包括眼部表型和功能评估 Kif4.1在Müler细胞中进行通路,但将工作从糖尿病视网膜病变延伸到AD。 晚发性AD(LOAD)是AD最常见的表现形式,遗传学在AD的发病机制中起着关键作用。 载脂蛋白e4(Apoe4)为主导因子。模式生物的发展及对迟发性的评价 阿尔茨海默病(模型-AD)是一个正在开发下一代小鼠模型的联盟 与这些模型中的各种表型的负载和特征相关。我们将利用这一独特的模式- AD资料:比较APOE4KI(LOAD-RISK)和APOE3KI(LOAD-RISK)小鼠的眼部表型 中性)。我们的务实研究设计将首先通过一系列视觉功能测试来表征这些小鼠, 探索它们的视网膜转录组以寻找神经变性的标志,并与脑组织的转录组进行比较 研究Müler细胞中的Kir4.1通道,其中APOE4主要集中在Müler细胞。在第二组研究中,我们将 对这些小鼠进行高脂饮食治疗,以研究高血糖环境下的视网膜功能,并进行测试 APOE4基因的存在是否会导致最常见的糖尿病视网膜病变(DR)表型 糖尿病并发症。上述研究设计是基于我们的初步数据,这些数据显示了一种血管 在APOE4动物模型中,高脂饮食导致脑部缺陷和血糖升高。为了确保 为了项目的成功,我们聚集了一支眼睛和AD研究方面的专家团队。 本增刊的研究将以多种方式推动AD研究领域的发展:(1)视网膜研究 血管系统可能有助于AD的早期诊断;(Ii)转录学将识别AD中改变的新靶点 视网膜,这将有助于了解该病的发病机制和未来的药物开发;(Iii)脑Kir4.1 通道在AD中下调;然而,APOE4如何影响其功能尚不清楚。我们的研究将 研究这一方向的机制;(Iv)DR是一种失明的眼睛状况,AD患者 我们的研究将阐明这两种病理之间的联系;(V)我们的 研究将有助于模型AD的目标,即表征AD模型的表型,并建立 目视评估未来模式的范例。

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of the pharmacist-managed cardiovascular risk reduction services on diabetic retinopathy outcome measures.
药剂师管理的降低心血管风险服务对糖尿病视网膜病变结果测量的影响。
  • DOI:
    10.18549/pharmpract.2019.1.1319
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Weber,ZacharyA;Kaur,Palakpreet;Hundal,Amrita;Ibriga,SomnoomaH;Bhatwadekar,AshayD
  • 通讯作者:
    Bhatwadekar,AshayD
Pharmacist-Managed Diabetic Retinopathy in Hispanic/LatinX Population.
药剂师管理的西班牙/拉丁裔人群糖尿病视网膜病变。
  • DOI:
    10.1177/08971900221136897
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    1.3
  • 作者:
    Patel,Janvi;Gonzalvo,JasmineD;Eckert,GeorgeJ;Schmelz,AndrewN;Bhatwadekar,AshayD
  • 通讯作者:
    Bhatwadekar,AshayD
Anti-integrin therapy for retinovascular diseases.
  • DOI:
    10.1080/13543784.2020.1795639
  • 发表时间:
    2020-09
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Bhatwadekar, Ashay D.;Kansara, Viral;Luo, Qianyi;Ciulla, Thomas
  • 通讯作者:
    Ciulla, Thomas
Circadian rhythm disruption results in visual dysfunction.
  • DOI:
    10.1096/fba.2021-00125
  • 发表时间:
    2022-06
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
  • 通讯作者:
RNA therapeutics for retinal diseases.
  • DOI:
    10.1080/14712598.2021.1856365
  • 发表时间:
    2021-05
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Gemayel MC;Bhatwadekar AD;Ciulla T
  • 通讯作者:
    Ciulla T
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ashay D Bhatwadekar其他文献

Ashay D Bhatwadekar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ashay D Bhatwadekar', 18)}}的其他基金

miR-92a as a biomarker of diabetic retinopathy
miR-92a 作为糖尿病视网膜病变的生物标志物
  • 批准号:
    10677876
  • 财政年份:
    2021
  • 资助金额:
    $ 39.63万
  • 项目类别:
miR-92a as a biomarker of diabetic retinopathy
miR-92a 作为糖尿病视网膜病变的生物标志物
  • 批准号:
    10477379
  • 财政年份:
    2021
  • 资助金额:
    $ 39.63万
  • 项目类别:
miR-92a as a biomarker of diabetic retinopathy
miR-92a 作为糖尿病视网膜病变的生物标志物
  • 批准号:
    10297984
  • 财政年份:
    2021
  • 资助金额:
    $ 39.63万
  • 项目类别:
Short-Term Training in Ophthalmology Research for Medical Students
医学生眼科研究短期培训
  • 批准号:
    10615001
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
Circadian Rhythms in Müller Cell Dysfunction
Müller 细胞功能障碍的昼夜节律
  • 批准号:
    10186751
  • 财政年份:
    2017
  • 资助金额:
    $ 39.63万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 39.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了